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Proteomics
May One Day
Revolutionize
Cancer Detection,
Staging, and
Prognosis
by Katie Prout Matias

M

any cancers progress
silently, not making themselves known until they
reach an advanced stage.
For example, in 75% of women with
ovarian cancer, the disease has already
advanced beyond the earliest and most
treatable stages by the time it is diagnosed.
The five-year survival rates of patients
with ovarian cancer who were diagnosed
early and those diagnosed later—90%
versus 35%, respectively—underscore the
need for an effective early detection method.
(Continued on next page)
Dr. Gordon Mills, a professor in the Department of
Molecular Therapeutics, and his colleagues have identified
protein biomarkers in ovarian and breast cancers that may
one day be used in screening blood tests.
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Proteomics May Revolutionize Cancer Detection, Staging, and Prognosis
(Continued from page 1)

But what if a simple finger prick
could be used to detect ovarian cancer,
as well as every other kind of cancer?
The beginnings of what could become
a revolution in cancer screening can
be seen in studies like those being
performed at The University of Texas
M. D. Anderson Cancer Center in
which researchers have been able to
detect cancer by the presence of
patterns of abnormal proteins in the
blood.
According to Gordon Mills, M.D.,
Ph.D., a professor in the Department
of Molecular Therapeutics at M. D.
Anderson, every tumor comes into
contact with the bloodstream, so it
should be possible to detect in a person’s
blood the proteins produced by the
tumor as well as the subtle changes in
other proteins caused by the tumor cells.
A wealth of information lies hidden
inside the proteome—a universe of
proteins even more vast and fluid than
the genome—and proteomic discoveries have the potential to affect the
entire spectrum of cancer research
and care.
At M. D. Anderson, researchers
are studying the modifications,
functions, and interactions of the
estimated one and a half million
proteins in the human body and are
exploring how protein biomarkers
and patterns might be used to detect,
stage, and predict the outcomes of
tumors, as well as to enhance drug
efficacy and develop novel targeted
therapies.
Detection
In a study of the early detection
of ovarian cancer, Dr. Mills and
researchers from the National Cancer
Institute (NCI) and the Food and
Drug Administration (FDA) compared protein patterns in the blood
of patients with ovarian cancer with
those in the blood of healthy volunteers. Using the abnormal protein
patterns they found in the patients
with cancer, the researchers developed
a test that correctly identified all 50
cases of ovarian cancer in their study,
including those in the earliest stages.
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“The question that hasn’t been
resolved is how many different proteins
one will have to look at,” Dr. Mills said.
In the ovarian cancer study, the investigators were able to identify the presence
of cancer in most of the malignant
cases by looking at just five proteins.
Preliminary research shows that
there may be as many as ten protein
biomarkers of breast cancer, said Dr.
Mills, who collaborated with the same
teams from the NCI and the FDA as well
as with researchers from Duke University
and M. D. Anderson to investigate
protein markers in breast cancer. Dr.
Mills said a blood test for these markers
might one day be used in place of
mammography or in cases where the
mammographic results are in question.
Protein blood tests might also
one day replace invasive screening
techniques such as colonoscopy.
“Having the general population
of the United States undergo

colonoscopy—an invasive procedure
that requires an anesthetic and has
complications associated with that and,
occasionally, with the procedure itself—
for a disease that has a total prevalence
in the population of about 6% is not a
very satisfying situation,” said Stanley
Hamilton, M.D., professor and head of
the Division of Pathology and Laboratory Medicine at M. D. Anderson. Dr.
Hamilton is researching the use of
proteomic serum screening to detect
protein markers in colorectal cancer.
People who have the protein markers
would then undergo a colonoscopy,
but those who did not could be spared
the procedure.

Staging and prognosis
Prostate cancer is the only cancer
for which a blood protein screening
test is already commonly used. But
although the prostate-specific antigen
(PSA) test is remarkably good at
detecting prostate cancer, it is a
very poor marker of prognosis,
said Wadih Arap, M.D., Ph.D.
In a recent study, Dr. Arap
and Renata Pasqualini, Ph.D.,
both professors of medicine and
cancer biology in the Department
of Genitourinary Medical Oncology,
screened patients with prostate
cancer for patterns of antibodies
against a certain protein and found
that high levels of the antibodies
correlated with a poor prognosis
as well as with advanced disease.
“The novel aspect of this work
is that we’re not looking at the
expression of the gene or the protein
but at how the body is responding
to it by producing antibodies,”
said Dr. Pasqualini.
Using protein antibody production to determine whether a tumor
is aggressive or likely to metastasize
would allow clinicians to create
tumor profiles and tailor therapy
accordingly. In the case of prostate
Dr. Howard Gutstein, an associate professor
cancer, oncologists could decide to
in the Department of Anesthesiology, is studying
forgo a prostatectomy in cases where
protein changes in brain cells that mediate opiate
the disease is too advanced for the
tolerance. Here, rat cells treated with morphine
procedure to be curative, said Dr.
(panel B) show different protein expression levels
than do control cells treated with saline (panel A). Arap.

Dr. Renata Pasqualini (left) and Dr. Wadih Arap, professors of medicine and
cancer biology at M. D. Anderson, retrieve samples from a cell line bank stored in liquid
nitrogen to use in an experiment. In a recent study, they found that high levels of antibodies against a certain protein correlated with a poor prognosis as well as with advanced
disease in patients with prostate cancer.
Drug efficacy
All too often, drugs given to patients
with cancer do not perform as hoped in
some patients or lose their effectiveness
after some initial activity. By looking
at what happens to proteins before,
during, and after drug administration,
researchers hope to understand how
a drug works or why it does not work.
For example, Howard Gutstein,
M.D., an associate professor in the
Department of Anesthesiology at M. D.
Anderson, is studying protein changes
that occur in the cells that mediate
opiate tolerance. “[Cancer pain] destroys whatever quality of life patients
have, and opiates are the best drugs we
have to treat that pain. They’ve been
in use for thousands of years,” Dr.
Gutstein said. Knowing the mechanisms
involved in opiate tolerance would
allow researchers to selectively prevent
tolerance to the analgesic effects of the
drug but not to adverse effects such as
depressed breathing, said Dr. Gutstein.
In the case of therapeutic drugs,
clinicians could avoid giving unneces-

sary, toxic treatments if they knew
beforehand whether the drug would
work in a particular patient based upon
his or her specific protein patterns.
“The goal is to find out if a patient
has resistance to certain drugs or if
chemotherapy will work. If we can
find a marker before starting treatment,
that would be helpful in preventing
unnecessary treatments for certain
patients,” said Ryuji Kobayashi, Ph.D.,
a professor in the Department of
Molecular Pathology and director
of the Proteomics Program at M. D.
Anderson. Dr. Kobayashi is researching
biomarkers in pancreatic, breast, and
ovarian cancers and in glioblastoma.
Monitoring a drug’s effects on
proteins during treatment could
help clinicians determine if the right
amount of the drug is getting to the
tumor and even identify new therapies.
Studying the drug’s mechanism and
the proteomic changes may reveal
new molecular targets upstream or
downstream of the intended target,
said Dr. Hamilton.

Challenges ahead
The proteome dwarfs the genome in
size and complexity. Because it took
many years and people working around
the clock to map the human genome,
“trying to do a proteome project boggles
the mind,” said Dr. Gutstein, who
pointed out that an estimated 10,000 to
15,000 proteins are expressed in every
cell in the body and that the proteome
differs in every cell type and between
healthy and sick individuals.
Furthermore, proteins can be
altered in many ways, and their multiple
interactions with other proteins as
well as with genes adds to the complexity of mapping the proteome. In fact,
Drs. Arap and Pasqualini think it would
be impossible to list all the proteins
in the body. “The same protein may
have 20,000 different forms,” said
Dr. Arap.
According to Dr. Kobayashi—
who improved the in-gel digestion
technique, which is now the standard
technique used in proteomics, and
proved the method several years before
the term “proteomics” was born—
continuing to develop extremely
sensitive and high-throughput technologies that can analyze many proteins
simultaneously will be the key to
progress.
“The rapidly emerging technologies
around proteomics have the potential
to give us a much greater window on
both normal and abnormal cellular
function,” Dr. Mills agreed. “That
window will provide incredible data of
what is happening in the cancer cells:
What are the predisposing events?
What are the early initiating events?
What are the events that allow that cell
to progress? Can the cell metastasize?
The ability to start looking at things on
a much more global basis is producing
a level of excitement we have not
had in the past.” ●
FOR MORE INFORMATION, contact Dr. Mills
at (713) 792-4687, Dr. Hamilton at
(713) 792-2040, Dr. Arap at (713) 7923871, Dr. Pasqualini at (713) 792-3872,
Dr. Gutstein at (713) 792-5037, or
Dr. Kobayashi at (713) 745-3363.
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Depression in Patients with Cancer
by David Galloway

I

t is perfectly normal for
someone with cancer to
be sad, to cry, to grieve,
and to be angry. Physicians
expect these reactions to a cancer diagnosis or news of disease
progression. But when such
reactions persist, it should
raise a red flag.
“There is no such thing as a ‘rational’
or ‘understandable’ major depression—
ever,” said Laura Sherman, M.D., an
assistant professor in the Department of
Neuro-Oncology, Section of Psychiatry,
at The University of Texas M. D.
Anderson Cancer Center. “Just because
a depression might have been triggered
by cancer does not mean that it should
not be treated as a separate medical
problem.”
“It’s like saying, ‘I hit you on the head,
so of course you have pain. You have a
reason for your pain, so I’m not going to
give you a Tylenol. If you didn’t have a
reason, I would treat it,’” Dr. Sherman
said. “And that makes no sense.”
Using the rigid criteria usually
applied in psychiatry, the rate of
depression in patients with cancer could
be as low as 5%, said Michael J. Fisch,
M.D., M.P.H., an assistant professor
in the Department of Palliative Care
and Rehabilitation Medicine at M. D.
Anderson. The actual rate is between
15% and 25%, however, because
diagnosing depression in patients with
advanced cancer calls for a slightly
different application of the criteria.
“If you are used to doing office-based
psychiatry, and you are not used to
caring for people in the last few months
of life, then you may have trouble
applying what you know to those kinds
of patients,” Dr. Fisch said. The diagnosis can be complicated by the fact that
some of the usual symptoms of depression can be mimicked or concealed by
the effects of cancer and cancer therapy.
4
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Debra Sivesind, M.S.N., (standing) a clinical nurse specialist in the Department of
Palliative Care and Rehabilitation Medicine, leads a guided imagery class at the Place…
of wellness at M. D. Anderson. Guided imagery, a complementary therapy that can help
some people relax and manage stress, is sometimes recommended for patients with
depression.
Some physicians are uncomfortable
asking their patients about depression.
“It’s safe to ask about it,” Dr. Fisch said,
adding that asking opens the door for a
patient to discuss the issue. The physician can then decide whether the
severity of the symptoms expressed
indicates a need for counseling or
medication.
Still, it can be a challenge to get
some patients to open up. A patient

who is asked about feeling depressed
or hopeless in the presence of his wife
might fear that acknowledging such
feelings would send the message that he
had given up or that he didn’t think his
marriage and family were good enough
reasons to strive to live longer. Another
patient might think that an expression
of hopelessness would make her oncologist decide aggressive treatment of her
cancer was no longer worthwhile.

Symptoms of Major Depression
Depression is indicated if one or more of the following symptoms is present
for at least two weeks:
• A depressed mood for most of
the day and on most days
• Diminished pleasure or interest
in most activities
• Significant change in appetite
and sleep patterns
• Psychomotor agitation or slowing

• Fatigue
• Feelings of worthlessness or
excessive, inappropriate guilt
• Poor concentration
• Recurrent thoughts of death
or suicide
Source: National Cancer Institute

Is a Separate—and Treatable—Illness
To medicate or not to medicate
If the criteria for diagnosing depression in patients with cancer are unclear,
the rules of thumb for deciding whether
to prescribe antidepressants are even
less firmly established.
“When to give medication? I think
that every clinician might have a little
different threshold,” said Debra M.
Sivesind, M.S.N., R.N., C.S., a clinical
nurse specialist in the Department of
Palliative Care and Rehabilitation
Medicine at M. D. Anderson.
The types of medications used to
treat depression in patients with cancer
include selective serotonin reuptake
inhibitors, tricyclic antidepressants,
and to a limited extent, analeptic
agents such as amphetamines.
Several factors should be considered
when prescribing antidepressants to
patients with cancer. First, the antidepressant treatment chosen should target
the specific distressing symptoms the
patient is experiencing. Also, any
adverse effects of the medication should
be minimized and should not worsen
the patient’s health or exacerbate any
coexistent medical problems. Finally,
the patient’s other medications should
be evaluated before antidepressant
therapy is begun to avoid any potentially harmful drug interactions.
Many modes of treatment
Treating depression means more
than writing a prescription, however.
Studies have shown that the treatment
of depression is optimized when medication is combined with psychotherapy
or supportive counseling.
While Dr. Sherman calls herself
a “better-living-through-chemistry
person,” she embraces all modalities
of treatment. “If psychotherapy is going
to be helpful, great. If going to a support
group is up this person’s alley, fabulous.
Some people really like tai chi or
hypnotism. There are many different
avenues for treatment,” she said.
Among the complementary therapies
that can help some patients with
depression is guided imagery, which

“If you are used to doing
office-based psychiatry,
and you are not used to
caring for people in the
last few months of life,
then you may have
trouble applying what
you know to those
kinds of patients.”
– Michael J. Fisch, M.D., M.P.H.,
assistant professor,
Department of Palliative Care
and Rehabilitation Medicine

Sivesind teaches through M. D.
Anderson’s Place…of wellness. Guided
imagery exercises stimulate the creation
of positive mental images, which helps
some patients manage stress and relax.
“Guided imagery can be used to
stimulate all of the five senses,” Sivesind
said. “When I’m leading a group in
guided imagery, I will ask them to
imagine either a beach or the mountains, something that’s comforting and
relaxing for most people. So, in going to
the beach, you can taste the salt air, you
can feel the wind on your skin and the
warmth of the breeze, you can feel the
sand beneath your feet, you can hear
the waves, you can see the clouds
and sailboats.”

Experiencing pleasant images does
two things for the patients, Sivesind said.
First, it gives them control over something. “In the midst of being out of
control, their life getting absolutely
turned upside down with cancer, this
kind of exercise is a way to be in control,” she said. Second, guided imagery
can trigger the relaxation response, a
state of deep rest that alters physical and
emotional responses to stress. It brings
about decreases in the heart rate, blood
pressure, and muscle tension. “A relaxed
body is a healthy body,” Sivesind said.
“A relaxed body is probably in a better
place for healing, in a better place for
the chemotherapy to work.”
However, Sivesind cautions that
guided imagery is not for everyone.
“When people get relaxed, guess what?
That is where our emotions live,” she
said. “Some people don’t want to touch
those emotions, but these exercises may
be used to release emotions, which can
be healing.”
Different cancer,
different depression
The symptoms of depression may
vary according to the type of cancer a
patient has. Patients with pancreatic
cancer, for example, may show a blunted
affect and pronounced anhedonia, a
lack of interest or joy in things, Dr.
Sherman said. In contrast, a woman
with breast cancer may undergo a
sudden chemotherapy-induced menopause that triggers a depression with
marked emotional lability.
The incidence of depression also
varies by cancer type. Depression
accompanies breast cancer, certain
gynecologic cancers, and head and neck
cancers more frequently than other
cancers. It is not yet known whether
those associations result from the
chemistry of the tumors themselves
or from the chemotherapy regimens
patients receive.
Depression does not always follow
cancer. Sometimes, it precedes it. “In
pancreas cancer, there’s a pretty good
(Continued on page 6)
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Depression in Patients with Cancer
(Continued from page 5)

“Some people will say
you can’t treat depression
when a patient is dying.
Yes, you can. You
absolutely can.”
– Laura Sherman, M.D.,
assistant professor,
Department of Neuro-Oncology,
Section of Psychiatry

wealth of data showing that many of
these people, maybe up to 50%, have a
prodromal depression that happens to
them before they ever start having other
physical symptoms,” Dr. Sherman said.
“About six months before, sometimes
even longer, out of the blue, people who
never had depression before suddenly
have a full-blown major depression.”
More than a mental problem
Depression not only subjects a patient
to greater suffering in and of itself but
also hinders cancer treatment, Dr. Fisch
said. He cited a study by Musselman and
colleagues (New England Journal of
Medicine, March 29, 2001) that compared paroxetine with placebo in
patients receiving high doses of interferon as adjuvant therapy for melanoma.
“The people who got the antidepressant
were not only less depressed but were
more likely to stay on their therapy,” Dr.
Fisch said. “That is, depression interfered
with cancer treatment.”
Potentially even more important is
the idea that some depression medications also help fight other cancer
symptoms. Mirtazapine helps reduce
nausea and weight loss, and Dr.
Sherman is developing a protocol to
evaluate its use in fighting cachexia in
patients with pancreatic cancer.
Most important is that treating
depression in patients with cancer
might actually increase survival rates.
Studies have shown that patients with
untreated depression do poorly, but it is
6
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not clear whether that is a result of a
lack of compliance or something else.
Other studies have suggested a link
between psychosocial interventions and
survival. Dr. Sherman plans to look at
the possibility of a survival benefit in
her pancreatic cancer protocol.
No need to be miserable
The treatment of depression in dying
patients is not a losing battle, Dr.
Sherman said. “Some people will say
you can’t treat depression when a
patient is dying,” she said. “Yes, you can.
You absolutely can.” Fast-acting antidepressants such as paroxetine and
citalopram can be administered in
combination with psychostimulants
such as methylphenidate to elevate a
patient’s mood within just a few days,
Dr. Fisch said.
“There is nothing that says we have
to absolutely be miserable as we die,” Dr.
Sherman said. “A lot of the people I’ve
worked with feel almost fortunate in a
way. They say, ‘I know that I have this
time to make up with people I’ve had
arguments with, I have this time to be
close to my family.’ They focus on what
is important in life. For some people, it’s
a very rich, rewarding experience. Just
because they’ve got a terminal illness
doesn’t mean they can’t enjoy life.” ●
FOR MORE INFORMATION, contact
Dr. Sherman at (713) 792-7546,
Dr. Fisch at (713) 792-3936, or
Debra Sivesind at (713) 745-4556.

Risk Factors for
Depression in
Patients with Cancer
Cancer-Related Risk Factors:
• Depression at time of cancer
diagnosis
• Poorly controlled pain
• Advanced stage of cancer
• Additional concurrent life
stressors
• Increased physical impairment
or discomfort
• Pancreatic cancer
• Being unmarried and having
head and neck cancer
• Treatment with certain chemotherapeutic agents, including
the following:
– Corticosteroids
– Procarbazine
– L-Asparaginase
– Interferon-α
– Interleukin-2
– Amphotericin B

Risk Factors Not Due
to Cancer:
• History of depression:
– Two or more episodes in a
lifetime
– First episode early or late
in life
• Lack of family support
• Family history of depression or
suicide
• Previous suicide attempts
• History of alcoholism or drug
abuse
• Concurrent illnesses that
produce depressive symptoms
(i.e., stroke or myocardial
infarction)
• Past treatment for psychological
problems
Source: National Cancer Institute

PHYSICIANS: THIS PATIENT INFORMATION SHEET IS YOURS TO COPY AND PASS ON TO PATIENTS.

Facing Fatigue When You Have
Cancer: What Can You Do?

E

ven a minor illness, like a cold, can drain a person’s
energy. So it’s no wonder that the fatigue that accompanies cancer can sometimes be as debilitating as the disease
itself. Patients with cancer often describe the way they
feel as “completely exhausted” or “drained.” They talk about being
mentally “sluggish” and “easily distracted.” Their fatigue, they
say, occurs after the slightest exertion and is rarely relieved by rest.
Fortunately, not everyone with cancer experiences this type of
fatigue, and those who do can take steps to combat its effects.
What causes fatigue?
Cancer-related fatigue has
many causes. One source is the
disease itself; for example,
tumors can produce toxic
substances that interfere
with normal body functions. Chemotherapy and
radiation therapy can lead to
nausea, dehydration, loss of
appetite, difficulty breathing
and sleeping, infection, anemia, pain,
and changes in metabolism, all of which
are potential sources of fatigue. Hypothyroidism, the decrease in physical
activity that frequently follows a
diagnosis of cancer, and medications for
pain and depression may cause fatigue.
Finally, the anxiety, stress, and depression that often accompany cancer and
its treatment can result in fatigue.
How does fatigue take its toll?
People with cancer are affected by
fatigue in many ways. For example,
they may be too tired to perform daily
tasks, to eat as they should, or to get to a
clinic or hospital for treatment. Extreme
fatigue may cause them to miss work or
quit altogether, which can affect their
insurance coverage and their finances.
They may not have the energy to
interact socially, causing them to
withdraw from friends and family
when they most need support.
What can be done
to combat fatigue?
No magic pill exists to cure cancerrelated fatigue. However, if you are

coping with debilitating fatigue, there
are things you can do to lessen the
effects:

Cancer-Related Fatigue
Information Sources
■ Fatigue Clinic at M. D. Anderson

■

■

■

■

1 Communicate with your
medical team and insist
on getting help. Some
medications can help increase
energy. Your doctors and other healthcare professionals can treat the symptoms of fatigue and often the source, but
first they must be aware of how you feel.

2 Take charge of your own
well-being.
• If possible, exercise lightly. Light
exercise such as walking can actually
decrease fatigue. Exercise can also
improve your appetite and self-esteem.
• Get plenty of sleep and rest. Take
naps if you need to, but don’t sleep
so much during the day that you
can’t sleep at night.
• Eat as well as you possibly can. Eat
several small meals a day if eating
three large ones makes you uncomfortable. And drink lots of liquids.
• Be realistic about what you can do.
Accept that you need to conserve
your energy for what is most important. Prioritize your activities.
Plan your day so that you are active
when you have the most energy.
• Find ways to enjoy yourself and the
company of your family and friends.
• Stay under your doctor’s care after
your treatment has ended.
• Try to stay positive, and remember
that for most people, the fatigue
does go away in time.

■

Cancer Center
(713) 792-2340
(Patients must be referred by a physician.)
National Cancer Institute*
(800) 422-6237 (Cancer Information
Service)
www.cancer.gov
American Cancer Society*
(800) 227-2345 (National Hotline)
www.cancer.org
National Comprehensive Cancer Network*
(888) 909-6226
www.nccn.org
The Oncology Nursing Society
www.cancersymptoms.org
Cancer Care*
www.cancercare.org

*Information also available in Spanish.

• Consider trying complementary
therapies such as relaxation techniques, self-hypnosis, meditation,
or yoga.

3 Accept the help of others.
Your family and friends no doubt want
to help you and may not know how, so
accept their offers to run errands and
take care of whatever they can. Find
out what your community offers in
the way of transportation to and from
treatments and appointments. And
consider joining a support group; being
with others who have similar issues
can be helpful to you and to your
loved ones. ●
For more information, contact
your physician or contact the
M. D. Anderson Information Line:
392-1611 within
✆ the(800)
United States, or
(713) 792-6161 in Houston
✆ and
outside the United States.
May 2003
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Proteomics: The Creation of a New Field of Study
Ryuji Kobayashi, Ph.D.
Professor, Department of
Molecular Pathology
Director, Proteomics Program
Exactly 50 years
after Watson and
Crick reported their
discovery of the
structure of DNA,
the Human Genome
Project was completed. The project,
which identified
about 28,000 human
genes, has had an enormous influence
on the biological sciences. In the 1990s,
scientists spent more time in the laboratory
cloning new genes. Now, with genome
sequencing and highly sensitive and highthroughput mass spectrometry techniques,
scientists have more time for functional
studies, including the study of proteomics.
The term “proteome” was coined less
than ten years ago to describe the set of
proteins encoded by the genome.
Proteomics, the study of the proteome,
started from the large-scale identification
of proteins separated by two-dimensional
gel electrophoresis. Proteomics now includes not only the analysis of all expressed
proteins but also the traditional study of
proteins, such as protein identification in
complexes and functional studies related
to protein structure.
M. D. Anderson Cancer Center’s
Proteomics Program, launched in the fall
of 2001, is involved in many basic science
and clinical research projects because of
the state-of-the-art instrumentation and
technology it offers. In the area of transla8
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tional research, the program’s focus is
to discover new biomarkers for early
diagnostic and drug sensitivity screening.
The availability of genome sequences
brought about new technological developments in protein analysis, most notably
mass spectrometry, which rapidly replaced
the Edman degradation technique after
nearly 50 years of dominance. Mass
spectrometric methods match the masses
of fragmented peptides with the calculated
masses from fragments of proteins in the
DNA-protein database. The use of mass
spectrometry also merged the fields of
protein chemistry, physics, chemistry,
biomedical sciences, and clinical research.
History teaches us that new insights and
discoveries often arise from the interface
of different fields of science.
Mass spectrometry is very sensitive, but
techniques utilizing immune reactions are
even more sensitive. Therefore, current
goals in protein biomarker research are
finding the markers in blood or body fluid
using mass spectrometry, identifying the
peptide or protein, and then making
antibodies to validate the protein and to
use for clinical testing. An alternative
method is to obtain protein profiles or
fingerprints by mass spectrometry, which
statistical bioinformaticians can analyze
to identify cancer-specific patterns.
We in the Proteomics Program begin our
collaborations with clinicians by listening to
their needs and explaining what we can do.
Together, we develop research plans and any
new technologies needed to put the plans
into action. Through this and other team
efforts at M. D. Anderson, we hope to one
day be able to control cancer or eliminate
it altogether.
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